Semaglutide Launch: Indian Pharma Stocks Poised for Growth, Analysts Predict

• Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Glenmark in focus after generic Semaglutide launches post-patent expiry.
• Generic versions introduced at steep discounts (₹1,290-₹8,000/month) compared to innovator drug (₹8,800-₹16,400/month).
• Vials are the most affordable option (₹1,290-₹1,750/month), while pen devices offer convenience at a premium (₹1,800-₹8,000/month).
• Market segmentation: Alkem, Natco, Eris, Glenmark as low-cost disruptors; Zydus in mid-tier; Sun Pharma, Dr Reddy's in premium generics.
• Analysts expect market to be volume-driven, potentially growing sixfold from ₹1,400 crore to ₹8,300 crore, with long-term potential of ₹28,500 crore.